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Abstract
Purpose of the review Idiopathic pleuroparenchymal
fibroelastosis (IPPFE) is a rare fibrosing lung disease, affect-
ing the visceral pleura and the subpleural parenchyma with an
upper lobe predilection, included as a distinct clinicopatholog-
ic entity in the latest international multidisciplinary classifica-
tion of the idiopathic interstitial pneumonias (IIP). We aim to
summarize the current evidence on IPPFE, in terms of clinical
features and potential treatments.
Recent findings Overall, there is increasing awareness of
PPFE in association with a separate ILD pattern. Although
an agreed consensus on diagnosis has yet to be defined, a list
of radiological and histopathological criteria has been pro-
posed. Due to the unfavorable risk-benefit profile of surgical
lung biopsy in a significant proportion of patients, a potential
role for transbronchial lung cryobiopsy has been suggested.
At present, lung transplantation remains the only curative
option.
Summary The increasing awareness of this condition among
specialists has led to more frequent identification of IPPFE.
Large international studies are needed to better characterize
pathogenesis and pheno/endotypes of disease, a key step to-
wards the development of effective treatments.
Keywords Pleuroparenchymal fibroelastosis . Idiopathic
interstitial lungdisease .Review .Diagnosis .Clinical features
Introduction
Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial
lung disease, characterized by dense fibrosis of the visceral
pleura and the subjacent lung parenchyma, with a striking
upper lobe predominance. Although sporadic cases of upper
lobe dominant fibrosis of unknown origin had been previously
published [1], Amitani et al. first described this peculiar
condition in a series of patients in 1992 [2]. Since then, a
number of similar cases have been reported in the Japanese
literature under the term of “Amitani’s disease” or idiopathic
“pulmonary upper-lobe fibrosis” (PULF). The currently ac-
cepted term PPFE first appeared in the English literature later,
in 2004, when Frankel et al. reported five cases of an “idio-
pathic pleuroparenchymal fibroelastotic syndrome with
unique pathology” that could not be classified into any of
the previously recognized interstitial pneumonias. Although
the acronym refers to a specific morphological pattern,
PPFE is now widely considered as a distinct clinicopatholog-
ical entity, with definite radiological and pathological charac-
teristics, and has been included in the latest international mul-
tidisciplinary classification of the idiopathic interstitial pneu-
monias (IIP), in the rare entities section [3]. To date, little more
than one hundred cases have been reported overall in the pub-
lished literature, but increasing awareness of this entity among
specialists will likely lead to more precise epidemiological
estimates on its actual occurrence.
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The etiology has yet to be clearly established, but a large
proportion of reported PPFE cases has been described in as-
sociation with lung, bone marrow, and hematopoietic cell
transplantations [4], in association with a number of chemo-
therapy drugs [5, 6], as well as with occupational exposures
such as aluminosilicate dust [7]. In the case series by Reddy
et al. [8••], approximately half of cases reported a history of
recurrent lower respiratory tract infections, suggesting that
repeated inflammatory damage caused by pulmonary infec-
tions may contribute to the development/progression of
PPFE in a proportion of patients. PPFE has also been reported
in association with a variety of separate ILD patterns, includ-
ing idiopathic pulmonary fibrosis (IPF) [8••, 9•, 10].
Moreover, it can occur in the context of familial forms of
IIP, mostly in young females [11, 12], suggesting the potential
role of a genetic predisposition. When none of the associated
conditions are identified, PPFE is considered idiopathic
(IPPFE). In keeping with the scope of the present review, we
will mainly focus on IPPFE, summarizing current evidence
and latest data on clinical features, radiological characteristics,
histological findings, differential diagnosis, prognosis, and
potential treatments.
The Clinical Spectrum
IPPFE usually presents in adults, but the age at onset is highly
heterogeneous, ranging from 13 to 87 years, with a median
value of approximately 53 years [13]. In particular, a bimodal
distribution of age at presentation has been observed, with an
earlier peak in the third decade, and a later one in the sixth
decade. A part from a female predominance in younger pa-
tients, the overall male to female ratio does not reveal a sig-
nificant gender predilection [14•]. Cigarette smoking does not
appear to be a risk factor. Indeed, PPFE mostly occurs in non-
smokers [15].
The main clinicopathologic features are summarized in
Table 1. Clinical features include exertional dyspnoea, cough,
weight loss, and chronic dull pleuritic pain, which may intensi-
fy over time, even in absence of an underlying pneumothorax.
Episodes of uni- or bilateral pneumothoraces occur in up to one
third of patients. Moreover, the spontaneous co-occurrence of
pneumothorax and pneumoperitoneum has been recently de-
scribed [16]. Pneumothoraces in these subjects rarely resolve
spontaneously, and persistent air leaks are often observed.
Patients are often slender and may present with
plathythorax, especially in advanced stages. Such a deformity
of the thoracic cage, measured as a reduced ratio of the
anteroposterior to the transverse diameter at computed tomog-
raphy (CT), has been defined as “flat chest” by the authors
who first identified this peculiar physical finding. The flat-
tened thoracic cage may worsen during the disease course
along with the functional decline, suggesting that an acquired
defect due to the decreasing volume of the upper lobes is a
more likely explanation than a congenital predisposition [17].
On physical examination, inspiratory crackles are rare and
Table 1 Main clinicopathologic features of idiopathic pleuroparenchymal
fibroelastosis (IPPFE)
Demographic aspects









Chronic dull pleuritic pain (occasionally sharp)
Weight loss
Signs
“Flattened” thoracic cage (or “plathythorax”)
Slender habitus
Bibasal crackles, if usual interstitial pneumonia (UIP)-like changes in lower
lobes
Functional parameters
Restrictive ventilatory impairment: disproportionate reduction in forced
vital capacity (FVC) compared to diffusing capacity of carbon monoxide
(DLCO), with KCO (DLCO/VA) trends towards supernormal values
Increased ratio of residual volume/total lung capacity (RV/TLC)
Gas analysis
Earlier stages: normal pressure of oxygen (Pa O2), with mild increase in the
partial pressure of carbon dioxide (PCO2), with a preserved
alveolar-arterial gradient of oxygen (A-aDO2)
Advanced stages: hypoxemia with hypercapnic respiratory failure
Serum biomarkers
Elevated surfactant protein D (SP-D)
Normal Krebs von den Lungen-6 (KL-6), or slightly increased in advanced
stage
Increased titres of a variety of serum auto-antibodies
Imaging features
Upper lobe bilateral, irregular pleural thickening, and dense reticular
fibrosis of subjacent lung parenchyma
Clear demarcation between abnormal and normal lung
Hila retracted upwards with distortion of the lung architecture
Overall volume loss and reduced ratio of the anteroposterior to the
transverse diameter
Interlobular septal thickening, small foci of consolidation, large cysts, and
multiple bullae may be observed
Uni- or bilateral pneumothoraces may occur
Coexistent interstitial involvement of the lower lobes (usually UIP-like
changes) in a proportion of cases
Pathologic findings
Fibrous thickening of the visceral pleura with elastic fibers
Homogeneous, dense, intra-alveolar fibrosis with septal elastosis (twice that
observed in idiopathic pulmonary fibrosis)
Transition from abnormal lesions to normal tissue typically abrupt
Mild, sparse mononuclear lymphocytic infiltration
Sparse fibroblastic foci
Partial stenosis of pulmonary vessels, both arterial and venous
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may be the expression of concomitant usual interstitial pneu-
monia (UIP)- or non-specific interstitial pneumonia (NSIP)-
like changes in the lower lobes. Digital clubbing is usually
absent.
Lung function tests are usually characterized by a restric-
tive ventilatory impairment, with markedly decreased forced
vital capacity (FVC) and slightly reduced total lung capacity
(TLC). The ratio of forced expiratory volume in one second/
FVC (FEV1/FVC) is increased, as is the ratio of residual
volume/TLC (RV/TLC), possibly resulting from the compen-
satory hyperinflation of lower lobes due to the fibrotic col-
lapse of the upper sections of lungs. Watanabe et al. recently
investigated the potential coexistence of small airways dis-
ease, usually characterized by an increased RV/TLC ratio, in
a series of nine patients with IPPFE, but did not identify any
radiological signs of air trapping, pathological evidence of
bronchiolitis, or functional response to bronchodilators [18].
The diffusing capacity of carbon monoxide (DLco) is overall
decreased, with preserved KCO (DLCO/VA), as observed in
restrictive impairments [2]. Indeed, because of an element of
extrapulmonary restriction caused both by the pleural fibrosis
and the thoracic cage abnormalities described above, there
may be a disproportionate reduction in FVC compared to
DLCO, with the resulting KCO edging towards supernormal
values (A/N).
In the earlier stages of the disease, arterial blood gas anal-
ysis usually documents a normal partial pressure of oxygen
(Pa O2) and a trend towards a mild increase in the partial
pressure of carbon dioxide (PCo2) with a preserved alveolar-
arterial gradient of oxygen (A-aDO2) [18]. Oxygen
desaturation on a six minute walk test (6MWT) is rare. This
particular blood gas profile is different from that observed in
the other interstitial lung diseases, characterized by decreased
values of both PaO2 and PCo2 and early desaturation on ex-
ertion. The tendency towards hypercapnia with a normal A-
aDO2 gradient in the early stages is again likely related to the
significant component of extrapulmonary restriction. With the
progression of the fibrotic process, hypoxemia with hypercap-
nic respiratory failure occurs in the advanced stages.
Elevated serum levels of surfactant protein D (SP-D) may
be observed, and Krebs von den Lungen-6 (KL-6) seems to
increase as the disease progresses, possibly as expression of
alveolar type II cell injury [19]. Increased titres of a variety of
serum auto-antibodies may also be detected in a minority of
cases, possibly reflecting a pathogenetic role of immune dys-
regulation [8••, 15].
Imaging Features
Chest high resolution CT (HRCT) findings are highly sugges-
tive and include bilateral, irregular pleural thickening and
dense reticular fibrosis of subjacent lung parenchyma with
upper lobe predominance. The presence of a clear
demarcation between the abnormal and normal lung is a char-
acteristic feature (Fig. 1). Wedge-shaped pleural densities ad-
vance along parenchymal septa and tend to retract the hila
upwards with distortion of the lung architecture. Further asso-
ciated features are interlobular septal thickening, small foci of
consolidation, and volume loss. Moreover, large cysts and
multiple bullae may be observed, possibly associated with
the high occurrence of pneumothoraces in these patients,
along with an altered resistance of the pleura to mechanical
stress. Dilated proximal airways, with free standing bronchi-
ectasis (Fig. 1a), are frequently observed, possibly as a conse-
quence of recurrent infectious episodes [20]. The free standing
airway dilatation should not be confused with the traction
bronchiectasis seen on a background of interstitial fibrosis.
As reported above, reduced diameters of the thoracic cage
are frequently described.
A coexistent interstitial involvement of the lower lobes
away from the pleuroparenchymal fibroelastotic changes is
described with increasing frequency in the literature, with
the ILD pattern usually reminiscent of UIP- or NSIP-like
changes (Fig. 1b) [9•, 10]. Extension of a PPFE pattern to
the lower lobes has been demonstrated in a subgroup of pa-
tients [21]. These data have been recently confirmed in a rel-
atively large series of Japanese patients (n=21), reporting an
equal involvement of upper and lower lobes in approximately
one third of cases [22].
Histological Pattern
The main histological features are fibrous thickening of the
visceral pleura and homogeneous, dense intra-alveolar fibrosis
with septal elastosis, sharply separated from the adjacent
“spared” lung parenchyma. The transition from abnormal le-
sions to normal tissue is, indeed, typically abrupt. A mild,
sparse mononuclear lymphocytic infiltration may be also de-
scribed, as well as partial stenosis of pulmonary vessels, both
arterial and venous. Other upper lobe changes include foci of
intra-alveolar fibrosis with septal elastosis with perilobular or
bronchocentric distribution. Elastic fibers (EF) within fibrosis
are easily identified by using specific stains, such as orcein or
Verhoeff van Gieson stains (Fig. 2a, b). Although experienced
pathologists may be able to recognize the characteristic fea-
tures of PPFE on a simple haemotoxylin and eosin stained
slide, routine staining for EF in the case of predominantly
pleural and subpleural lesions is highly recommended to aid
in differential diagnosis. The main mimic in this context is a
UIP pattern, be it idiopathic or secondary. Areas of fibroblastic
proliferation can be observed in some cases, but the limited
number of foci usually permit to distinguish between the two
morphological entities [14•]. Moreover, although deposition
of elastin is described in UIP, a recent quantitative assessment
showed that the amount of EF in IPPFE upper lobes was twice
than that observed in IPF and remained significantly higher
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even when the comparison was made with IPPFE lower lobes
[23]. Further relevant differences include the temporal hetero-
geneity of the fibrosing process and the striking remodeling of
lung parenchyma, with architectural disruption. It is worth
underlining, however, that these two patterns are not mutually
exclusive, as recent studies have revealed that their coexis-
tence may be more frequent than previously thought [9•,
20]. Elements of diffuse alveolar damage, alveolar hemor-
rhage, and obliterative bronchiolitis can be observed, although
this seems to occur in transplant patients, rather than in IPPFE
[24].
Diagnosis
Currently, an agreed consensus statement on IPFFE diagnosis
has yet to be defined, although a list of radiological and his-
topathological criteria have been proposed and widely
adopted in the published literature. In 2012, Reddy et al.
[8••] suggested both radiological and morphological criteria
for “definite,” “consistent with,” and “inconsistent with”
PPFE. With reference to imaging, “definite” PPFE referred
to cases with pleural thickening and subpleural fibrosis con-
fined, almost exclusively, to the upper lobes; “consistent with”
did not necessarily require an upper lobe predominance and
allowed features of coexistent disease elsewhere; “inconsis-
tent with,” when the above described features were absent.
Histological criteria for “definite” PPFE included upper zone
a
b
Fig. 2 a Section of a lung biopsy which displays subpleural and
centrilobular fibroelastosis. The vessels show mild fibrointimal
thickening (white arrow). b At higher magnification, the distinctive
pattern of PPFE comprises intraalveolar fibrosis and interstitial elastosis
(IAFE). At the edge, between the IAFE and the lung parenchyma,
fibroblast foci are identified (black arrow)
Fig. 1 a (Trasversal section) pleuroparenchymal irregularity with peaks
of fibrosis around the pleural surfaces consistent with PPFE. The
proximal airways are abnormally dilated (bronchiectatic), possibly the
consequence of repeated infections. b (Sagittal section) there is
pleuroparenchymal fibrosis with a clear mid and upper zone
distribution. In the costophrenic angles, there is evidence of interstitial
disease (limited honeycombing) with no conspicuous pleural disease
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pleural fibrosis with subjacent intra-alveolar fibrosis accom-
panied by alveolar septal elastosis; a “consistent with” pattern
was assigned when intra-alveolar fibrosis was present but it
was not associated with pleural fibrosis, was not predominant-
ly beneath the pleura, or was not in an upper lobe biopsy;
“inconsistent with,” when the required features described
above were absent. Further histological criteria for PPFE di-
agnosis were proposed by Rosembaum et al. in 2015 [21] as
follows: 1) fibrous interstitial pneumonia with 80%
fibroelastic changes in nonatelectatic (collapsed) lung; 2)
subpleural and/or centrilobular distribution; 3) overall inflam-
mation absent to mild; 4) no specific lobe predilection, typi-
cally multilobar; 5) Rare or no granulomas.
While a definite diagnosis of IPPFEwould ideally require a
combination of radiological and morphological features, in a
substantial number of cases, a surgical lung biopsy is not
obtained, due to the unfavorable risk-effectiveness profile.
IPPFE patients often present with advanced disease with lim-
ited ventilatory reserve, and, because of the absence of a cu-
rative treatment, the risks related to the surgical procedure,
including potentially prolonged post-operative iatrogenic
pneumothorax, can be perceived to overcome the potential
benefits. On the other hand, particularly when features of an
associated ILD pattern without clear-cut diagnostic features
are present away from the PPFE changes, a surgical lung
biopsy can offer the advantage of obtaining samples from
different lobes. More recently, transbronchial lung cryobiopsy
(TBLC) has been proposed as a valuable, less invasive, sam-
pling technique in the diagnostic work-up of ILDs [25].
Although the pooled proportion of post-procedural pneumo-
thorax onset from meta-analyses of literature is not negligible
(up to 12%) [25, 26] and its frequency may well be higher in
the context of PPFE, the risk-effectiveness profile may be
reasonable in selected, healthier IPPFE patients. However, as
the clinical and radiological features in these patients are often
highly suggestive, the need for a morphological assessment
has been debated [24] and a label of “consistent with PPFE”
for cases without biopsy has been proposed. At any rate, it is
unquestionable that a multidisciplinary approach is mandatory
for a conclusive diagnosis of IPPFE.
A list of differential diagnoses should be considered while
evaluating cases with suspected IPPFE. Asbestos exposure, a
previous history of tuberculosis, as well as signs and symptoms
suggestive of sarcoidosis and connective tissue disorders
should be carefully investigated. Appropriate laboratory tests
for autoimmune screening and bronchoalveolar lavage (BAL)
analysis may be required in selected contexts. The apical cap is
an idiopathic lesion of lung apices, in the form of a subpleural
pyramidal scar, histologically characterized by subpleural fibro-
sis and curls of EF. It can be differentiated from IPPFE, as it
does not involve the pleura circumferentially, and it occurs
mostly in older males with a history of smoking and tends not
to progress over time [14•].
Association with other ILD Patterns
A substantial proportion of patients with IPPFE presents with
UIP-like features in the lower lobes [10]. Nakatani et al. ret-
rospectively reviewed 205 patients with ILD undergoing lung
biopsy and identified 12 PPFE cases, of which 11 had inter-
stitial lung disease in the lower lobes (five definite UIP, four
possible UIP, one NSIP, one unclassifiable) [10]. Oda et al.
conducted a retrospective review of patients with a histologi-
cal UIP pattern, diagnosed with IPF, in order to identify the
proportion of subjects meeting the above mentioned radiolog-
ical and morphological criteria for PPFE and to assess whether
they presented with distinctive characteristics. Nine of 110
patients (8.2%) met both radiological and histological criteria
for IPPFE diagnosis (PPFE/UIP). When compared to the re-
maining 99 “pure” IPF subjects (IPF/UIP), patients with
PPFE/UIP showed flattened chest, a lower BMI, a higher
complication rate of pneumothorax and pneumomediastinum,
and distinctive functional features, including a preserved
DLCO, an increased RV/TLC ratio, and a higher PCO2.
Moreover, although not significantly different, the median
survival time tended to be shorter. The presence of PPFE
was identified in a substantial proportion (33.6%) of large
group (N=274) of consecutive patients with a diagnosis of
IPF at a single Institution (Royal Brompton Hospital). In this
study, the presence of PPFE was associated with a significant-
ly more rapid functional decline and worse survival, even after
adjustment for background ILD severity, as assessed by CT
extent [20]. Whether PPFE in association with a background
UIP pattern should be routinely considered as a poor prognos-
tic marker of IPF, and/or as separate entity requiring target
treatment, remains to be established.
Associated Conditions
It is well known that a PPFE pattern may be also associated
with a large variety of conditions, although a clear causative
relationship has yet to be established. So far, the strongest
association seems to be with a previous organ transplant. In
a recent retrospective study, PPFE was detected as a late com-
plication in 7.5% of lung transplantation recipients and in
0.2% of hematopoietic stem cell transplantation recipients
[4]. Concurrent histologic features in these patients included
acute and/or organizing diffuse alveolar damage, character-
ized by the presence of intra-alveolar fibrinous exudates
appearing to merge into PPFE lesions and constrictive bron-
chiolitis. PPFE may, thus, represent the final expression of a
multifactorial intra-alveolar lung injury, as a number of possi-
ble causes may contribute to its onset, including previous che-
motherapy regimens, radiation, recurrent infections, and graft
versus host disease. Previous exposure to alkylating agents,
such as cyclophosphamide and carmustine, has been de-
scribed as potentially associated with PPFE, although the time
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between the last drug intake and the first noticeable symptom
ranged from 1 to 16 years. As mentioned above, a concomi-
tant role of recurrent infections cannot be ruled out, with a
proportion of patients reporting recurrent infections during
the course of disease [8••]. In particular, Aspergillus and
Mycobacterium avium intracellulare infections have been re-
ported [15, 27].
Prognosis and Management
Prognosis has been reported as highly variable and largely
unpredictable. So far, limited data are available on IPPFE
evolution, as, in most of the studies, the overall survival rate
is reported together for idiopathic and secondary forms.
Overall, the clinical course in idiopathic cases seems to be
rapidly progressive, especially in young females with a famil-
ial background and in the subgroup of patients with lower lobe
UIP features [9•, 20]. However, there are cases of IPPFE
which remain relatively stable in the longer term. Due to the
long subclinical phase, IPPFE is commonly diagnosed in the
advanced stages, making a reliable assessment of disease be-
havior since its first onset difficult [2]. Yoshida et al. have
recently identified two distinct patterns of lung function de-
cline in their cohort of patients, a rapid decline in FVC over a
short period, and a slow decline over a longer period, although
the latter was observed only in one quarter of subjects [22].
At present, management is challenging, as no treatment has
yet been shown to modify the natural course of disease.
Patients have been empirically treated with corticosteroids,
immunosuppressive agents, and N-acetyl cysteine, with tran-
sient or no benefit [28]. A potential efficacy of pirfenidone in
preventing lung function decline has been suggested in a re-
cent case-report [28]. An interesting temporal relationship was
observed in this patient between lung function decline and
pirfenidone intake, as the disease stabilized while taking the
drug, progressed after drug discontinuation due to liver toxic-
ity, and then stabilized again once pirfenidone was
reintroduced. Supportive care includes oxygen therapy in case
of respiratory failure and careful infection control. In ad-
vanced stages, lung transplantation should be considered, as
cases of successful lung transplants in IPPFE patients have
been described [15].
Conclusions
IPPFE is a rare condition, characterized by distinctive clin-
ical, radiologic, and pathologic features that warrant its
inclusion as a separate entity in the latest classification of
IIP. Although IPPFE pathogenesis remains largely unclear,
the heterogeneous spectrum of clinical presentation and
behavior suggests that it may represent the final expression
of a variable interplay between environmental exposure,
immune dysregulation, and genetic predisposition. The in-
creasing awareness of this condition among specialists has
led to the more frequent identification of IPPFE, revealing
that it may not be as rare as previously perceived. Large
international studies are urgently needed to better charac-
terize the different pheno/endotypes of disease and to de-
velop effective treatments.
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